Effect of MK-801 on the antinociceptive effect of [D-Ala(2),N-MePhe(4), Gly-ol(5)]enkephalin in diabetic mice.
The role of N-methyl-D-aspartate (NMDA) receptors in supraspinal and spinal sites on the reduction of supraspinal micro-opioid receptor-induced antinociception in diabetic mice was examined. The antinociceptive effect of i.c.v. [D-Ala(2), N-MePhe(4), Gly-ol(5)]enkephalin (DAMGO, 20 pmol) in diabetic mice was significantly less than that in non-diabetic mice. The antinociceptive effect of i.c.v. DAMGO (20 pmol) was significantly and dose dependently reduced by i.c.v. (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801) in both non-diabetic (0.03-0.3 nmol) and diabetic mice (0.1-3.0 nmol). While the antinociceptive effect of i.c.v. DAMGO (10 pmol) was significantly enhanced by i.c.v NMDA (0.01-0.1 nmol) in non-diabetic mice, the same doses of i.c.v. NMDA had no significant effect on the antinociceptive effect of i.c.v. DAMGO (20 pmol) in diabetic mice. In non-diabetic mice, the antinociceptive effect of DAMGO (20 pmol, i.c.v.) was dose dependently reduced by intrathecal administration of MK-801 (0.1-1.0 nmol). The antinociceptive effect of DAMGO (20 pmol, i.c.v.) was dose-dependently enhanced by MK-801 (0.1-1.0 nmol, i.t.) in diabetic mice. Furthermore, NMDA (0.1 nmol, i.t.) significantly enhanced the antinociceptive effect of DAMGO (10 pmol, i.c.v.) in non-diabetic mice. However, in non-diabetic mice, the antinociceptive effect of DAMGO (40 pmol, i.c.v.) was dose dependently reduced by NMDA (0.03-0.3 nmol, i.t.). These results suggest that NMDA receptor function in supraspinal and spinal sites appear to be modulated differently by the diabetic state, and this functional modulation may play an important role in the reduction of supraspinal micro-opioid receptor-induced antinociception in diabetic animals.
Department of Pathophysiology and Therapeutics, Faculty of Pharmaceutical Sciences, Hoshi University, 4-41, Ebara 2-chome, Shinsgawa, Tokyo 142-8501, Japan.
Ko
K
Zushida
Junzo
J
Kamei
D000818:Animals; D003921:Diabetes Mellitus, Experimental; D016291:Dizocilpine Maleate / Q000494:pharmacology*; D004347:Drug Interactions; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000494:pharmacology*; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D010146:Pain / Q000139:chemically induced / Q000517:prevention & control*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D017450:Receptors, Opioid, mu / Q000187:drug effects*
D016194:Receptors, N-Methyl-D-Aspartate; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D016291:Dizocilpine Maleate